Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer

Imaging Appearance and Clinical Impact of Preoperative Breast MRI in Pregnancy-Associated Breast Cancer

“…In our study population of 53 women, most patients presented with a palpable ab-normality, confirming the findings of previous reports [8,9,19]. The most common abnormality was invasive ductal carcinoma, with more than half of the cancers showing a positive hormone receptor status, which is also similar to the findings of previous studies [5,8,19,20].…”

“…PABC fortunately is rare, although when it does occur it is often aggressive, with some studies suggesting poorer outcomes than those noted for age-and stage-matched control subjects [4,5,19,20]. In our study population, most women had no known risk factors at the time of diagnosis, with only 23% having a family history of breast cancer in a first-degree relative and with only two patients (4%) known to be carriers of the BRCA mutation.…”

Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype

“…Pregnancy-associated breast cancer (PABC), also known as "gestational breast cancer" is defined as breast cancer diagnosed either during pregnancy or up to one year postnatal (20) and affects around 1 in 3,000 pregnant women (21). In comparison with nulliparous women, breast cancer in pregnant women is histologically similar; approximately 75%-90% of the tumors are invasive ductal carcinomas with no-special-type (NST) (21)(22)(23)(24)(25)(26). While, invasive lobular carcinoma (ILC) and other histological types are uncommon in patients with PABC (23,(27)(28)(29).…”

Immediate breast reconstruction following mastectomy in pregnant women with breast cancer

“…Patients in the non‐IR group were noted to have higher clinical stage disease compared to the IR group. Patients with BCP may present at a more advanced stage and with more aggressive biological subtypes , which may lower likelihood of being offered IR. In this cohort, there were no patients with locally advanced disease who underwent IR.…”

“…Only one study to date has evaluated the safety of IR during pregnancy and most patients are advised to consider delayed reconstruction . A greater understanding of the safety and outcomes of local and systemic therapy for patients diagnosed with BCP has led to expanded treatment options and suggests a pregnant breast cancer patient can receive safe and timely standard therapies using a multidisciplinary approach . As IR may be a safe option for non‐pregnant patients, the aim of this retrospective study was to evaluate the safety of IR in pregnant patients undergoing mastectomy as well as short term maternal, fetal, and reconstructive outcomes.…”